On July 3, 2024, Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics Inc (NASDAQ:APGE), sold 5,995 shares of the company. The transaction was filed on the same day with the SEC. Following this transaction, the insider now owns 294,793 shares of Apogee Therapeutics Inc. Warning! GuruFocus has detected 1 Warning Sign with APGE. Apogee Therapeutics Inc is engaged in the development of therapeutic treatments for various medical conditions. This biopharmaceutical company focuses on innovative solutions to address unmet medical needs. The shares were sold at a price of $37.6, valuing the transaction at approximately $225,402. This sale has adjusted the insider's stake in the company significantly. Apogee Therapeutics Inc currently has a market cap of approximately $2.143 billion. Over the past year, the insider transaction history at Apogee Therapeutics Inc shows a balanced activity of buys and sells among the insiders. There have been 2 insider buys and 2 insider sells. The recent transaction by Carl Dambkowski marks a continuation of this trend. The valuation metrics of Apogee Therapeutics Inc, such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are essential for investors to consider. The stock's valuation can also be assessed using the GF Value, which provides a reference point for high-quality investment decisions. Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) This insider sale might be of interest to investors tracking insider behaviors as an indicator of the company's future performance and alignment of interests between shareholders and management. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus.
Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...